CNA Finance Exclusive

Gevo Inc GEVO Stock News

Gevo, Inc. (NASDAQ: GEVO)

Gevo is having yet another incredibly rough day in the market today. In fact, over the past 3 days, it seems like the stock has been spiraling out of control. Before I get into the story, I want to thank my friends Brad and Richard from StockTwits for trying to help me find the reason the declines are happening. With that said, I believe that I’ve pinpointed the problem. Here’s what I believe is going on with GEVO.

Trade smarter and make more money with Tradespoon!

Most Of This Is Speculation

First and foremost, I want to say that there have been no news releases. What I’m going to let you in on is my personal opinion. Unfortunately, I am not an insider. However, I did have a recent discussion with Dr. Gruber, the CEO of Gevo. This, in combination with something that Richard pointed out to me, leads me to an interesting conclusion. Nonetheless, this is, for the most part, me speculating, as I’ve searched and searched but can’t seem to find an answer.

Interesting Points From Richard And Brad About GEVO

As mentioned above, I’ve been going back and forth with two investors in regard to what’s been going on. Earlier today, Richard made a great point. Here’s what he sent me in an email:

I haven’t found anything conclusive either. I thought it may have been an institutional holder but the largest holder has just 900K. I have watched trading closely and there large blocks hitting. As soon as the bid up ticks, they pound it. Very strange!”

Here’s another interesting point from Brad…

I don’t know either…, so odd.

Http://www.biofuelsdigest.com/bdigest/2016/10/13/cellulosics-india-goes-huge/

this is recent industry news….; and far from bad for Gevo…”

What I Gathered From The Last Discussion With Pat

The last discussion I had with Gevo’s own Pat Gruber was a great one. To read it, click here. In the conversation, what I believe to be one of the most important things that I gathered has to do with how the conversation has changed.

At this point, we know GEVO can survive. That’s no longer a question, and that’s great. However, the question has gone from how we get from surviving to thriving. At the end of the day, things are going in the right direction. However, for everything to get into full swing, the company needs more capital, as you would expect from a company in this phase of growth.

Responses After The Interview

As always, directly following the publication of the interview, my email and StockTwits feed blew up with responses. One of the big ones I saw time and time again was that investors were concerned about the idea that more public offerings were coming down the line. Not to mention that a reverse split is probably going to be the end result of the NASDAQ listing compliance issues. Of course, Pat didn’t discuss either one of these. What he did say to these topics was essentially that GEVO would be dumb to let themselves get delisted and that capital formation is a must.

Bringing It All Together

With large blocks of stock being sold at every uptick as Richard pointed out, it’s clear that traders are manipulating the heck out of this thing right now. However, this has to go deeper than that. There has to be an explanation for the stock giving up so much in the past three days.

While the news surrounding GEVO has been overwhelmingly positive, as Brad points out, I think investors are simply getting cold feet. It’s been a while since we got any new PR from the company. We know that capital formation is coming down the line sometime, and it’s likely to happen soon. With little by way of PR, investors are left to their imaginations with regard to how capital formation might happen. My hypothesis is that it started with day traders playing the game and taking their profits. On top of that, actual investors in the stock started to get cold feet as their imaginations weighed heavy. As a result, we’re seeing big blocks of stock flying out of the window.

Don’t waste your time! Click here to find winning trades in minutes!

Is It Time To Be Worried?

At this point, I maintain my opinion on Gevo. At the end of the day, the company has an incredible product and is heading in the right direction. Then again, I’m looking long term. Of course there are going to be risks when capital formation is a must. These risks are concerning to some investors, and that’s understandable. However, after my many talks with Pat Gruber, Shawn Severson, and others from the GEVO team, I honestly believe that the company has what it takes to get over the capital formation hurdle and thrive on the other side. It’s only a matter of time. However, in the mean time, we’re going to have good days, and we’re going to have bad.

[Image Courtesy of Pixabay]


Twitter TWTR Stock News

Twitter Inc (NYSE: TWTR)

Twitter is having an incredibly rough time in the market at the moment, and for good reason. The company has been climbing, as it was announced that companies like Alphabet, Salesforce.com, and others were interested in acquiring it. However, one by one, these companies have backed off of the TWTR acquisition goal.

Salesforce Backs Off TWTR Acquisition Hopes

Trade smarter and make more money with Tradespoon!

Recently, we heard that Alphabet, Google’s parent company,  was no longer interested in acquiring Twitter. Of course, the stock took a dive on the news. Today, more news is coming out, and it’s not good. Earlier today FT reported that TWTR lost Salesforce.com as a possible buyer. After Alphabet dropped out of the race, the next company that was most likely to buy Twitter was Salesforce.com. However, with today’s news, that’s no longer the case. At this point, it seems as though an acquisition isn’t going to happen, and TWTR is doomed to further declines.

What We’re Seeing In The Market

As you could imagine, TWTR is taking a dive. Currently (1:38), the stock is trading at $16.73 per share after a loss of $1.06 per share (5.96%) thus far today.

What We Can Expect To See Moving Forward

Don’t waste your time! Click here to find winning trades in minutes!

At the end of the day, Twitter has one big problem. The company can’t seem to bring users in and retain them as active users on the network. As a result, growth simply can’t happen for long. Now, the company is in dire straights and has decided to sell. However, with Salesforce.com backing out of the running, the goal of being acquired seems to have slipped away. At the moment, things aren’t looking good for TWTR. So, I’m expecting to see more declines ahead!

[Image Courtesy of Pixabay]


ContraVir Pharmaceuticals CTRV Stock News

ContraVir Pharmaceuticals Inc (NASDAQ: CTRV)

ContraVir Pharmaceuticals is having an incredible day in the market today, and for good reason. Yesterday, the company reported interim data surrounding CMX157. Today, we’ll talk about the data, what we’re seeing from the stock, and what we can expect to see from CTRV ahead.

Trade smarter and make more money with Tradespoon!

CTRV Reports Positive Interim Data For CMX157

CMX157 is a treatment that ContraVir Pharmaceuticals has been working on for some time. The drug is designed for the treatment of HBV infections and is currently in the midst of an ongoing Phase 2a clinical trial. In the trial, the company is comparing the treatment to tenofovir disoproxil fumarate (TDF, also branded by Gilead as Viread) in chronically infected Hepatitis B patients.

In their announcement today, CTRV said that patients have successfully completed both dosages 5 mg and 10 mg. The company said that, on average, patients treated with CMX 157 showed an average of 99% reduction in HBV viral load compared to baseline.

Another very important factor here was the level of active tenofovir in the blood. Levels too high will generally lead to off-target side effects. So, naturally, the goal here was to show that active tenofovir in the bloodstream is relatively low following treatment. In their press release, CTRV announced that the results showed significant improvement over Viread by achieving similar antiviral activity while significantly reducing systemic tenofovir exposure. In a statement, James Sapirstein, CEO at ContraVir Pharmaceuticals, had the following to offer:

We are pleased and excited with these clinical results, as they demonstrate CMX157’s great potential in our ongoing effort to develop a cure for HBV… The significant viral load reduction and favorable safety at this low does of CMX157 speaks to the unique liver-targeting mechanism of our drug, which concentrates the antiviral activity of tenofovir in the liver, enabling anti-HBV efficacy at lower doses and minimal drug exposure to other tissues. We believe, based on the data that are being generated, that CMX157 has great potential as a safe and highly potent backbone of combination therapy against HBV.”

How The Stock Reacted To The News

One of the first things that we learn as investors is that the news moves the market. In this particular case, the news with regard to ContraVir Pharmaceuticals was overwhelmingly positive. For some reason, we’re seeing a delayed reaction, but that’s alright. Today, the stock is seeing the gains it deserves. Currently (12:43), CTRV is trading at $1.79 per share after a gain of $0.43 per share (31.84%) thus far today.

Don’t waste your time! Click here to find winning trades in minutes!

What We Can Expect To See Moving Forward

Moving forward, I have an overwhelmingly bullish opinion of what we can expect to see from ContraVir Pharmaceuticals. At the end of the day, the company is showing that its treatment works and, perhaps more importantly, is safer than one of the leading treatments on the market. That’s incredible news. After all, if they can compete in the HBV space, profits are surely coming down the line. All in all, I’m expecting to see gains out of CTRV.

[Image Courtesy of Wikimedia]


MannKind Corporation MNKD Stock News

MannKind Corporation (NASDAQ: MNKD)

MannKind Corporation has had a rough time in the market for a couple years at this point, and for good reason. The company simply can’t seem to sell its flagship product. As a result, the stock has taken a dive and is now trading in the penny category. However, there is one thing the company could do to return value to its shareholders. Today, we’ll talk about what that is, why MNKD needs to do it, and what I’m expecting to see from the stock ahead.

Trade smarter and make more money with Tradespoon!

MNKD Could Actually Sell Afrezza!

The one thing that MannKind could do to really return value to shareholders is to sell Afrezza. I’m not talking about selling it inhaler-by-inhaler to patients. No, I’m talking about selling the product as a whole, the asset, to another company.

Here’s the gist of it… MNKD simply can’t seem to sell their product to consumers. In the first go around, I stuck with the company as I believed that the issues were on Sanofi’s side. However, since the company started the second launch of the product, the launch in which it has control, we’ve seen nothing different. Sales growth isn’t there, and with a need to sell tens of thousands of prescriptions to stay above water, the company is in trouble. Chances of it reaching this mark are slim to none.

However, if MNKD was willing to sell the asset outright, there would be two big benefits:

  • Shareholder Value – First and foremost, if MannKind did sell Afrezza outright, the company would be able to use the proceeds from the sale to return value to shareholders. This may also give the company the ability to work on other treatments that may be easier to commercialize in the long run (for example, the EpiPen competition product they have mentioned).
  • Addressing Medical Needs – The truth is that there are several people that need a treatment like Afrezza. However, because of the poor commercialization effort by MNKD, these people don’t have it. By selling the asset, the buyer would likely know how to commercialize this type of product, bringing treatment availability upward, and making sure that those who need it, have it.

Why The Company Needs To Sell Afrezza

MNKD is in a very rough spot at the moment. With Afrezza’s underperformance, they are simply waiting for the sand to run out of the timer. At the end of the day, the company just doesn’t have the money to survive without positive sales, and it doesn’t have the capability to get people interested in the product. So really, there are a couple of feasible options that I can see here. Unfortunately, the best option is to sell the asset to a company that’s going to do something with it!

Don’t waste your time! Click here to find winning trades in minutes!

What I’m Expecting To See Ahead

I’ve tried to maintain a bullish opinion with regard to MNKD, but those efforts have proven to be unfruitful. At the end of the day, MannKind is not a company that’s thriving, and when it comes to surviving, they barely make the cut there. The bottom line is that the company is struggling and, until something big happens, will likely continue down the same path. All in all, I’m expecting to see further declines on the stock.

Update – CNA Finance Chief Strategic Analyst, Kenny Soulstring, has weighed in on MNKD. To see what he has to say, click here!  For a limited time, all analysis by Mr. Soulstring is offered 100% free. Get in while you still can by subscribing below!

* indicates required



[Image Courtesy of Wikipedia]


Ocular Therapeutix OCUL Stock News

Ocular Therapeutix Inc (NASDAQ: OCUL)

Ocular Therapeutix is having an incredibly strong day in the market today, and for good reason, the company announced a new strategic collaboration that’s causing excitement among investors. Today, we’ll talk about the collaboration and how OCUL has reacted to the news thus far.

Trade smarter and make more money with Tradespoon!

OCUL Enters Collaboration Agreement

As mentioned above, Ocular Therapeutix is having an explosive day in the market today after announcing a new strategic collaboration, option, and license agreement. The agreement was signed with Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN). According to the release, the two companies will work together on the development of a sustained release formulation of the vascular endothelial growth factor (VEGF) trap aflibercept. The medication is designed for the treatment of wet age-related macular degeneration (wet AMD). The company will also be targeting other serious retinal diseases.

While the formulation the companies are working on together is still in preclinical development, REGN already has a version of aflibercept approved by the FDA for certain indications. The brand is known as EYLEA. As a result, OCUL has quite a bit to benefit from this partnership.

On the other side of the coin, OCUL has a lot to offer as well. The company is currently in the process of developing proprietary sustained-release hydrogel-based drug delivery depots for intravitreal injection. These depots can be formulated with both small and large molecule pharmaceuticals.

With REGN already having the aflibercept and OCUL already working on the sustained release side of the coin, this is a match made in heaven. At the end of the day, the two are working to put their strengths together to create a sustained-release formulation of aflibercept.

Where’s The Money?

According to the agreement, Ocular Therapeutics has the ability to exercise a key option. Upon exercising the option, the company will receive a payment of $10 million from Regeneron, at which point the company would be responsible for funding development through Phase 1. Regeneron has agreed to fund subsequent development and commercial costs.

Also under the terms of the agreement, OCUL would be eligible to receive up to $305 million in milestone payments if the treatment is successful. This total is comprised of up to $155 million in development and regulatory milestone payments, $100 million for the first commercial sale, and up to $50 million in commercial milestones.

Key Statement

Along with the announcement of the collaboration agreement, Amar Sawhney, Ph.D., President, CEO and Chariman at OCUL, had the following to offer:

We have made considerable progress in developing our protein drug delivery platform at Ocular Therapeutix, so it is good to see an industry leader such as Regeneron recognizing the potential of this technology… We are excited to partner with Regeneron to develop a potential first-in-class sustained release protein-based anti-VEGF hydrogel injection for wet AMD, DME, RVO, and other serious retinal diseases. This sustained release formulation could have the potential to significantly reduce dosing frequency and subsequently reduce doctor visits, thus reducing the burden of care for patients, caregivers and physicians, and may decrease the likelihood of certain side effects associated with frequent intravitreal injections.”

Don’t waste your time! Click here to find winning trades in minutes!

How The Stock Reacted To The News

As investors, one of the first things that we learn is that the news moves the market. Any time positive news is released with regard to a publicly-traded company (like what was released today surrounding Ocular Therapeutix), we can expect to see gains in the value of the stock associated with the news. Well, that’s exactly what we’re seeing from OCUL today. Currently (10:46), the stock is trading at $7.49 per share after a gain of $1.18 per share (18.70%) thus far today.

[Image Courtesy of Wikipedia]


IntelliPharmaCeutics IPCI Stock News

IntelliPharmaCeutics International Inc. (NASDAQ: IPCI)

IntelliPharmaCeutics International is having an incredible day in the market today, and for good reason. In after-hours trading yesterday, the company announced that it had entered into an agreement with Mallinckrodt. Today, we’ll talk about the agreement, how the stock reacted to the news, and what we can expect to see from IPCI moving forward.

Trade smarter and make more money with Tradespoon!

IPCI Gains On Mallinckrodt Agreement

As mentioned above, IntelliPharmaCeutics is having a strong day in the market after the announcement of a new agreement. That agreement is with a company known as Mallinckrodt LLC (NYSE: MNK). Under the terms of the agreement, IPCI has granted Mallinckrodt an exclusive license to market, sell, and distribute multiple drug product candidates within the United States. Those candidates include:

  • Generic Seroquel – Quetiapine fumarate extended-release tablets have already been tentatively approved by the FDA.
  • Generic Pristiq – Desvenlafaxine extended-release tablets. This treatment currently has an ANDA under FDA review.
  • Generic Lamictal – Lamotrigine extended-release tablets. This treatment currently has an ANDA under FDA review.

This is a massive deal. After all, in the announcement, IPCI noted that, collectively, these products generate around $2.5 billion in sales every year in the United States.

Term Of Agreement And More

According to the release offered by IntelliPharmaCeutics, the agreement has a term of 10 years. In return for licensing and commercialization, Mallinckrodt has agreed to pay an upfront payment of $3 million. This payment will be made this month.

The agreement also includes a profit sharing arrangement with respect to the licensed products. Under the agreement, IPCI has agreed to manufacture and supply the licensed products on an exclusive basis. In return, Mallinckrodt has agreed not to work with any other supplier with regard to the licensed products to be marketed in the U.S.

Key Statements

Allong with the announcement of the agreement, we heard key statements from leaders of both companies. Here’s what they had to offer:

We are very pleased to establish this long-term commercial partnership with Mallinckrodt, which follows last week’s tentative approval for our generic Seroquel XR. Mallinckrodt is a respected pharmaceutical company with significant market presence in the U.S. This partnership provides further recognition of IntelliPharmaCeutics’ technology platform and pipeline. We look forward to the commercialization of generic Seroquel XR with Mallinckrodt following final approval.” – IPCI CEO Dr. Isa Odidi.

This agreement aligns well with our strategy of strengthening our Specialty Generics business and expanding our pipeline. If approved, these drugs will provide patients with alternative treatment options for central nervous system disorders… We look forward to working with IntelliPharmaCeutics to bring these products to market.”

How The Stock Reacted To The News

As you can see from the information above, the news surrounding IPCI was overwhelmingly positive. So, it’s only fitting that we see a positive response in the market. Currently (11:27), the stock is trading at $2.97 per share after a gain of $0.14 per share (4.95%) thus far today.

Don’t waste your time! Click here to find winning trades in minutes!

What We Can Expect To See Moving Forward

As mentioned in my last article about IntelliPharmaCeutics, my opinion with regard to the stock is overwhelmingly bullish. With today’s news, that opinion has been further validated. All in all, I’m expecting to see gains surrounding IPCI ahead.

What Do You Think?

Where do you think IPCI is headed moving forward and why? Join the discussion at StockTwits, Twitter, Facebook, orGoogle+!

[Image Courtesy of JPhotoStyle.com]

Tesaro TSRO Stock News

TESARO Inc. (NASDAQ:TSRO)

On Monday, Tesaro Stock closed higher by 18.79% after the company had announced over the weekend that its drug was successful in a clinical trial in patients with ovarian cancer. The results were outstanding, and a big reason why the stock closed higher for the day. What makes the results even more impressive is the fact that they were presented at a European Medical Conference. Original data was released earlier in the year, in June, but detailed results of the trial was released over the weekend. Even though a majority of these results were known, it didn’t stop the stock from big gains for the day.

Trade smarter and make more money with Tradespoon!

TSRO Trial Results

The phase 3 clinical trial was known as ENGOT-OV16/NOVA, and it recruited a total of 533 recurrent Ovarian Cancer patients. When it is said that patients have recurrent Ovarian Cancer, that means that no matter how many treatments they take, the cancer comes back after being eradicated from the body. Tesaro’s drug, niraparib, was combined with platinum-based chemotherapy. That combination was tested against the platinum-based chemotherapy alone.

The primary endpoint of the clinical trial was to assess the progression-free survival — PFS — of those patients taking niraparib compared to the chemotherapy. The trial was set up with two cohorts because TSRO was testing two sets of Ovarian Cancer patients. That means one set had the BRCA mutation version of the cancer, and the other set was the non-BRCA mutation cancer version. The trial was successful in both populations, which makes the results even that much more significant.

In the Ovarian cancer patients with the BRCA mutation, the median PFS for niraparib was 21 months compared to 5.5 months in the placebo side. Obviously the drug was clearly built for the BRCA Ovarian cancer patients. While the non-BRCA mutation didn’t succeed with as large as a gap in PFS like the BRCA group it was still successful. The non-BRCA group patients taking niraparbib achieved a median PFS of 9.3 months compared to placebo obtaining 3.9 months. Having both trials successful in Ovarian cancer is no easy feat at all.

Ovarian Cancer

There are around 200,000 cases of Ovarian Cancer per year in the United States. It is a difficult type of cancer to treat because there aren’t many treatment options other than platinum-based chemotherapy. It is also a type of cancer that is hard to detect because symptoms don’t become known until the cancer has spread to the pelvis and belly of the patient. The problem with that is that once it has spread to other parts of the body, it becomes a lot more difficult to treat. Surgery and chemotherapy are both current treatments but carry heavy risks. Especially chemotherapy which carried a lot of side effects. TSRO drug niraparib was safe for the most, but had some grade 3 and 4 adverse events reported in the trial. The investigator has noted that most of these were resolved by adjusting the dosage level of the drug.

Moving Forward

Don’t waste your time! Click here to find winning trades in minutes!

Tesaro has a lot going for its drug. With the results helping the stock post some gains, the truth is that there is another catalyst yet to come. That is TSRO stating that it will be able to complete its rolling FDA submission of its NDA for niraparib by the 4th quarter of this year. Considering that the drug was shown to be highly superior to current treatment options along with the fact that there weren’t very many safety issues, then it should be able to easily obtain FDA approval. The market opportunity for targeting Ovarian Cancer could be up to $1.4 billion. This drug has shown that it can help these patients with recurrent ovarian cancer over standard of care, and that will be key for its marketing success.


[Image Courtesy of Wikipedia]

Valeant Pharmaceuticals VRX Stock News

Valeant Pharmaceuticals Intl Inc (NYSE: VRX)

Valeant Pharmaceuticals is in the middle of one hell of a debate at the moment. As we know, about a year ago the company was caught in the midst of a scandal with a pharmacy known as Philidor. So, the term Philidor Scandal has been dubbed. Now, the fear is high while debates surrounding the company’s future swirl around the internet. So, what’s the deal? Is this an opportunity in the making? I think yes! Today, we’ll talk about why I see opportunity when I see VRX.

Trade smarter and make more money with Tradespoon!

It’s Time To Play The Buffet Game With VRX

Warren Buffett is a huge name in investing, and for good reason. The guy is an absolute genius that can turn pennies into dollars and dollars into millions! One of the lessons that he has taught the investing community is that sometimes risk is a good thing and that timing is everything. This is often interpreted by saying buy when fear is high and sell when greed is high. Well, when it comes to Valeant Pharmaceuticals, the fear is high.

Taking This A Step Further

Now keep in mind, Warren Buffet is not a dumb guy that struck it rich on a couple of good trades. Even if fear is high, he isn’t buying if there is no potential for massive gains in the future. In my opinion, that’s what makes VRX the perfect target for a Buffet-style profit play.

Think about it, the company’s stock has plummeted. In July of last year, the stock hit a peak at more than $257 per share. Currently (1:42), the stock is trading at $23.81, and that’s after some gains. Of course, the scandal was the reason for the declines. However, I believe that fears have gone far past realistic.

At this point, VRX really is an entirely different company in the way they operate. They’ve got new management, new strategies, and new concepts. However, the company still has the same smash-hit treatments that it had in the past. If any other company had a line up of products that was so impressive matched with an incredibly strong pipeline, we would see a much higher price. However, due to fears of legal actions coming down the line, investors are keeping the stock far lower than it should be at the moment.

Don’t waste your time! Click here to find winning trades in minutes!

This Is Creating One Heck Of An Opportunity!

While Valeant Pharmaceuticals may seem like something you would want to avoid like the plague, the truth is that there’s huge opportunity here. At the end of the day, I understand that the company was in the wrong, and a couple of years down the road it’s likely to be hit with big settlements as a result. However, at the moment, the company has plenty of time to prepare for the impending legal blues.

In the mean time, the opportunity surrounding the stock is incredible. VRX has been working to bring value back to shareholders through new agreements, leading to stronger product sales. Not to mention, the pipeline the company is working on is incredible and will likely lead to strong gains ahead. While in the short run this may be a risky play, I’m expecting to see big gains out of VRX in the long run.

What Do You Think?

Where do you think VRX is headed?

[Image Courtesy of Wikipedia]

Resolute Energy Corp REN, Chesapeake Energy Corporation CHK, Seadrill SDRL Stock News

Resolute Energy Corp (NYSE: REN) | Chesapeake Energy Corporation (NYSE: CHK) | Seadrill Ltd (NYSE: SDRL)

Resolute Energy, Cheasapeake Energy, Seadrill, and several others in the oil industry are having an amazing day in the market today. The gains are happening for good reason. A Saudi Arabian official made a shocking comment with regard to oil. Today, we’ll talk about the comment, why it was so shocking, what we’re seeing from oil and energy stocks as a result, and what we can expect to see from stocks like REN, CHK, and SDRL ahead.

Trade smarter and make more money with Tradespoon!

Surprising Comments Made By Khalid al-Falih Boost REN, CHK, and SDRL

Khalid al-Falih is the energy minister in Saudi Arabia. As such, anything he says with regard to the oil and energy market is likely going to be met with quite a bit of movement in the market. With that being said, Falih surprised oil and energy investors today, sending stocks like Resolute Energy, Chesapeake Energy, and Seadrill heading upward.

In a statement Falih spoke with regard to what he expects to see from the price of oil. In his comments, he caused excitement among REN, CHK, and SDRL investors by saying a 20% rally in crude oil prices was “not unthinkable…” In a key snippet from that statement, he had the following to say:

I think the role of responsible producers around the world, and Saudi Arabia considers itself to be the leading one, is to try to balance supply and demand in a very reasonable way…”

Why This Is So Surprising

The comments weren’t the only thing that sent REN, CHK, and SDRL upward.  Another reason these stocks went so high was the fact that the comments were so surprising. The truth is that, due to political conflicts, Saudi Arabia has been one of the key reasons that we’ve seen a continuation in declines in oil in the first place. Even after the OPEC deal was announced, there were still concerns that the deal would fall apart.

However, companies like Resolute Energy, Chesapeake Energy, and Seadrill – as well as their shareholders – are all given new hope. At the end of the day, Saudi Arabia seems to be taking a sincerely aggressive approach to improving the supply and demand of oil. As a result, there are less concerns that we’ll see further declines in the price of the commodity.

What We’re Seeing In The Market

As mentioned above, REN, CHK, SDRL, and several others in the oil and energy industry are seeing big gains today. After all, the news with regard to the balance of supply and demand in oil was overwhelmingly positive, and these companies are highly exposed to oil spot market prices. As a result, we’re seeing big gains today. Currently (12:51) REN, CHK, and SDRL are trading at $29.97, $6.58, and $2.68 per share respectively. This comes after respective gains in the amount of $0.46, $0.22, and $0.11 (1.56%, 3.45%, and 4.28%) so far today.

Don’t waste your time! Click here to find winning trades in minutes!

What We Can Expect To See Moving Forward

While I would not have imagined I would be saying this even 2 months ago, I have a relatively bullish opinion of what we can expect to see from Resolute Energy, Chesapeake Energy, and Seadrill ahead. Like most others in their industry, these companies have been put through the ringer. However, with the idea that the world’s largest oil producers are actually serious about improving supply and demand comes a whole new world for these companies. Oil will likely continue heading up in value, and REN, CHK, Seadrill, and other oil and energy companies will see great benefits.

What Do You Think?

Where do you think REN, CHK, and SDRL are headed? Join the discussion at StockTwits, Twitter, Facebook, or Google+!

[Image Courtesy of Wikipedia]

Bristol-Myers Squibb BMY Stock News

Bristol-Myers Squibb Co (NYSE: BMY)

Bristol-Myers Squibb is having a tremendously rough day in the market today, and for good reason. The company reported that an immune-based therapy it has been working on for the treatment of lung cancer has failed for the second time. Today, we’ll talk about the news, what we’re seeing from the stock as a result, and what we can expect to see from BMY ahead. So, let’s get right to it…

Trade smarter and make more money with Tradespoon!

BMY Announces Clinical Failure

As mentioned above, Bristol-Myers Squibb is having an incredibly rough day in the market today after announcing that a clinical trial has failed. For some time now, the company has been working on a drug known as Opdivo. The goal was that this immune-based therapy would be a strong treatment for lung cancer. The study, known as the Checkmate-26 study proved that the treatment was less effective than chemotherapy, the current standard of care.

During the study, BMY expected that it would at least prove that Opdivo was clinically superior in patients with high levels of a protein known as PD-L1. After all, it is expected that the levels of this protein in patients are a great indicator of how well immune-based therapies would work. However, in the trial, even those with elevated PD-L1 levels didn’t see a clinically superior result over chemotherapy. Ultimately, while the immunotherapy has worked in other cancers, the lung cancer indication simply doesn’t seem to be a fitting one.

Following the release of the results, Fouad Namouni, Head of Oncology Development at BMY, had the following statement to offer, and it summed things up perfectly:

We thought Opdivo could beat chemotherapy, and we have answered the question – for the broad population it is not enough…”

How The Stock Reacted To The News

At the end of the day, we know that the news moves the market. While positive news will generally lead to gains, the news surrounding Bristol-Myers Squibb simply wasn’t positive. Unfortunately, a treatment the company has invested tons of time and money into has proven ineffective, and that’s going to weigh heavy on the stock. Currently (11:20), BMY is trading at $50.10 per share after a loss of $5.33 per share (9.62%) thus far today.

Don’t waste your time! Click here to find winning trades in minutes!

What We Can Expect To See Moving Forward

While today’s news was far from positive for Bristol-Myers Squibb, my view on the stock remains relatively bullish. At the end of the day, the stock took a dive as punishment for their failure today. However, the company has built an incredible name for itself and has several approved treatments on the market. Not to mention, they also have a very strong pipeline. At the end of the day, you can’t hit a home run with every swing. In the world of biotechnology, there are going to be points at which companies strike out. Nonetheless, while BMY did strike out on Opdivo, the company has done an incredible job building its brand and becoming one of the larger contenders in the industry. All in all, I’m expecting to see gains ahead.

What Do You Think?

Where do you think BMY is headed? Join the discussion at StockTwits, Twitter, Facebook, or Google+!

[Image Courtesy of Flickr]

Thought Leader Discussions

Gevo, Inc. GEVO Stock News

0 4656
Gevo, Inc. (NASDAQ: GEVO) Before we get into this interview, I'd like to extend a special thanks to my friend Joey who both set up the...